OE			
O P EM125015763US	Application No.	Applicant(s)	
OCT 2.9 2008 Notice to Comply			
	10551667 Examiner	LU ET AL. Art Unit	
	Tracy Vivlemore	1635	
NOTICE TO COMPLY WITH REQUIREMEN			AINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES			
Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).			
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):			
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).			
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).			
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).			
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."			
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).			
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).			
☑ 7. Other: table III of the specification contains sequences lacking sequence identifiers.			
Applicant Must Provide: ☑ An initial or substitute computer readable form (CF	RF) ∞py of the "Sequence Listi	ng".	
An initial or substitute paper copy of the "Sequence directing its entry into the specification.	e Listing", as well as an am	endment spec	ifically
□ A statement that the content of the paper and corno new matter, as required by 37 C.F.R. 1.821(e) or 1			applicable, include
For questions regarding compliance to these requirements, please contact:			
For Rules Interpretation, call (571) 272-2510 For CRF Submission Help, call (571) 272-250 PatentIn Software Program Support			
Technical Assistance To Purchase Patentin Software	703-306-2600		
PLEASE RETURN A COPY OF THIS NOTIC	CE WITH YOUR REPLY		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: INTM/017

re patent application of

LU, PATRICK Y. et al.

Serial No.: 10/551,667

Filed: July 18, 2006

For: TARGETS FOR TUMOR GROWTH INHIBITION

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Mail Stop SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

- the submission, filed herewith in accordance with 37 C.F.R. §
 1.821(g), does not include new matter;
- 2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Date

Bridget Conroy

HARBOR CONSULTING IP SERVICES, INC. 1500A Lafayette Road, #262 Portsmouth, NH 03801 800-318-3021